Sharp Therapeutics Corp.
SHRX.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 266.70% | 212.14% | 368.29% | -7.79% | -26.25% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 54.96% | 76.55% | 121.23% | 34.72% | 26.69% |
| Operating Income | -54.96% | -76.55% | -121.23% | -34.72% | -26.69% |
| Income Before Tax | -61.63% | 7.48% | -112.24% | 12.49% | 25.38% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -61.63% | 7.48% | -112.24% | 12.49% | 25.38% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -61.63% | 7.48% | -112.24% | 12.49% | 25.38% |
| EBIT | -54.96% | -76.55% | -121.23% | -34.72% | -26.69% |
| EBITDA | -57.25% | -76.19% | -124.24% | -35.62% | -27.93% |
| EPS Basic | 95.92% | 99.06% | 99.09% | 99.46% | 77.34% |
| Normalized Basic EPS | 95.57% | 98.84% | 98.88% | 99.28% | 70.65% |
| EPS Diluted | 95.91% | 99.05% | 99.08% | 99.46% | 77.34% |
| Normalized Diluted EPS | 95.57% | 98.84% | 98.88% | 99.28% | 70.65% |
| Average Basic Shares Outstanding | 26.16% | 83.22% | 221.01% | 1,275.09% | 437.89% |
| Average Diluted Shares Outstanding | 26.16% | 83.22% | 221.01% | 1,275.09% | 437.89% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |